Initially, ASNS protein expression was thought to determine ASNase susceptibility in ALL [6]; however, recent studies have shown that promoter methylation, along with low ASNS expression, may become a better biomarker for predicting ASNase sensitivity [14,15,16]. The gene discussed is ASNS; the disease is acute lymphoblastic leukemia.